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ABSTRACT
Primary tumours of the heart are rare in children. Most of them are benign. Sarcomas predominate among ma-
lignant tumours and are characterised by disadvantageous prognosis, especially in the presence of metastases.
We present a case of a 16-year-old boy admitted to the hospital with signs of worsening exercise tolerance 
and suspected left atrial myxoma. The patient was urgently treated with cardiac surgery. Only partial tumour 
resection was possible. Rhabdomyosarcoma (RMS) embryonale was diagnosed. Stage IV of the disease was 
established (metastases to the left lung). A good initial response to chemotherapy was observed. In control stud-
ies, during the maintenance chemotherapy (15 months from the diagnosis of RMS) progression of the disease 
(PD) was found: right forearm tumour with metastasis near the left adrenal gland. Despite the intensification of 
treatment, there was resistance to successive lines of chemotherapy. The patient died of the disease progression.
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INTRODUCTION
Primary cardiac tumours are rarely diagnosed in the 
paediatric population. They represent about 0.027–0.32% 
of all childhood neoplasms [1]. The most common of 
these (90%) are benign tumours. Sarcomas, including 
rhabdomyosarcoma (RMS), as well as extremely rare cases 
of fibrosarcoma, synovial sarcoma, and granulocytic sar-
coma [2], dominate among malignant heart tumours [3].
Moreover, until now only single cases of secondary 
heart involvement by neuroblastoma, leukaemia, lympho-
ma, and melanoma have been reported [4]. Prognosis in 
sarcomas is still disadvantageous, especially in the pres-
ence of metastases. In stage IV the five-year survival rate 
is about 20–30% [5]. Only a few cases of disseminated 
form of RMS of the heart have already been described.
CASE REPORT
We present a case of a 16-year-old boy admitted with 
suspicion of left atrial myxoma with signs of gradually 
worsening physical exertion tolerance for three months. 
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There was systolic murmur over the apex of the heart 
in physical examination. No other abnormalities were 
found. Due to the increasing symptoms of heart failure, 
standard laboratory tests, electrocardiography (ECG), 
and transthoracic echocardiography (TTE) were per-
formed. ECG revealed the features of enlargement of the 
left atrium. In TTE a 6.3 × 6.1 × 4 cm tumour attached to 
the posterior lateral wall of the left atrium was visualised 
(Fig. 1). The tumour narrowed the mitral valve and the 
left ventricular outflow tract (Fig. 2). Based on the TTE 
image, left atrial myxoma was suspected. The patient was 
urgently qualified for cardiac surgery.
The tumour filling the left atrium of the heart was vi-
sualised intraoperatively. The main tumour mass was re-
moved, dissecting it from the posterior flap of the mitral 
valve. The tumour infiltrated the posterior wall of the left 
atrium. Complete resection was not possible. Postopera-
tive transoesophageal echocardiography (TEE) visualised 
acceptable mitral valve regurgitation (I/II grade). Histo-
pathological examination revealed RMS embryonale ana-
plastic variant (vimentin+, desmin+, myogenin+).
Computed tomography (CT) performed seven days 
after surgery showed: irregular masses in the left-poste-
rior part of the left atrium and a large amount of dense 
fluid in the pericardium corresponding to postoperative 
changes (Fig. 3), change in the sixth left lung segment 
(6 mm diameter) (Fig. 4), and thickened left adrenal 
gland with a nodule of 9 mm diameter. There were no 
abnormalities in bone scintigraphy or in the studies eval-
uating bone marrow (biopsy and trepanobiopsy).
Stage IV was determined. The CWS 2006 protocol for 
the high-risk group was initiated [6]. In a control CT scan 
performed in the ninth week of treatment, a reduction of 
the left lung lesion to 3.5 mm was observed. The change in 
the adrenal gland remained stable. According to the pro-
tocol, during the course of chemotherapy, the tumour site 
and the metastatic lesion in the left lung were irradiated 
(4140 Gy in 23 fractions) with a 6.15 MV photon beam 
from linear accelerator. In the next CT scan (eighth month 
of treatment) there was no previously described lung le-
sion, but a new small change (3 mm) was found. A nodule 
in the left adrenal gland was unchanged and was consid-
ered as independent of the sarcoma. During treatment 
FIGURE 1. Tumour of the left atrium with dimensions 6.3 × 6.1 × 4 cm 
visualised with transthoracic echocardiography
FIGURE 2. Narrowing of the mitral valve by the left atrial tumour 
visualised by transthoracic echocardiography with colour Doppler 
function
FIGURE 3. Postoperative changes in the heart in chest computed 
tomography scan
FIGURE 4. Metastatic change in the sixth left lung segment visuali-
sed in chest computed tomography scan
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several complications were observed, such as: leukopaenia 
(WHO grade IV), anaemia (WHO grade III), oral muco-
sitis, and lower left limb polyneuropathy. Cardiac compli-
cations (sinus tachycardia and diastolic dysfunction of left 
ventricle) developed in the sixth month of treatment. In 
a control physical examination (15 months after diagno-
sis of RMS) during maintenance chemotherapy with OTI/
OTE scheme [6] a tumour was found in the proximal part 
of the right forearm. Computed tomography revealed soft 
tissue tumour in the right forearm (5.2 × 4.2 × 9 cm) and 
a new nodular change near the left adrenal gland inde-
pendently of the previously described small stable tumour. 
Disease progression was confirmed by histopathological 
examination of the specimen from the tumour of the 
arm. Despite the intensification of treatment (second and 
subsequent lines of therapy), further progression was ob-
served. The patient died 12 months after disease progres-
sion, 27 months after diagnosis.
DISCUSSION
The presented case refers to a difficult clinical situa-
tion – a primary, incompletely removed RMS located in 
the heart of a child, with distant metastasis to the lung. 
Primary cardiac tumours, especially malignant, are ex-
tremely rare in the paediatric population [1, 3]. The de-
scription of this case can be used to analyse several im-
portant problems that appear during the diagnosis and 
treatment of this type of patient.
Histopathological examination revealed RMS embry-
onale anaplastic variant. Two main histological subtypes 
of RMS are distinguished: embryonal and alveolar. More 
favourable prognosis for the embryonal subtype has been 
shown [7], but anaplasia, found in 13% of patients with 
RMS embryonale, significantly worsens the results of 
treatment [8].
Before the cardiac surgery, the boy underwent the 
necessary set of tests enabling proper qualification. In re-
cent years, non-invasive methods of intracardiac tumour 
diagnostics have been extensively studied. They focus 
mainly on the assessment of tumour structure, its mobil-
ity, attachment to the heart wall, and its blood supply [9, 
10]. The primary aim is to differentiate between benign 
lesions (myxomas and intracardiac clots) and malignant 
tumours – in the paediatric population most often RMS. 
Early diagnosis makes it possible to choose the appropri-
ate treatment methods. However, despite this, the final 
diagnosis can only be made on the basis of histopatholog-
ical examination. The difference between the interpreta-
tion of echocardiography and the result of postoperative 
material analysis in this case confirms the effectiveness of 
the guidelines.
Accurate imaging also plays an important role in a pa-
tient’s qualification for appropriate adjuvant treatment. In 
the patient’s chest CT, a metastatic lesion in the left lung 
was detected, and the highest stage IV was determined. 
Proper diagnostic imaging also has proven prognostic 
value. Using general information about the patient and 
the results of imaging tests, assessment using the Oberlin 
risk criteria can be made [11]. Based on these criteria, 
the expected three-year event-free survival (EFS) was 
only 20%. Baseline prognosis in our patient was highly 
unfavourable.
Currently, the standard treatment in patients with pri-
mary disseminated RMS is combined therapy with surgi-
cal methods, radiotherapy, and chemotherapy [5]. In the 
above case the CWS 2006 protocol dedicated to paedi-
atric patients with high-risk RMS was applied. In recent 
years a frequently discussed topic has been the strategy 
of dealing with isolated metastatic changes in the lungs. 
This problem is clinically important. The lungs are the 
most common location of metastatic lesions in patients 
with RMS. An important document that raises this is-
sue is the report of the CWS study group [12]. The use 
of local treatment methods – radiotherapy and surgical 
procedures – is not associated with improved progno-
sis. In the presented case irradiation of both metastatic 
changes in the left lung and residual masses in the left 
atrium of the heart was performed, which was associated 
with cardiac complications observed in the sixth month 
of treatment – sinus tachycardia and diastolic dysfunction 
of the left ventricle. This procedure was motivated by the 
initially unfavourable prognosis in this patient. The pae-
diatric population is particularly at risk for cardiovascu-
lar complications during radiotherapy involving the chest 
region. Radiation-related heart disease can affect every 
heart structure and is mainly related to diffuse myocar-
dial dysfunction (observed in this case), pericarditis and 
pericardial fibrosis, premature development of coronary 
artery disease, and degeneration of the heart valves [13]. 
The early development of cardiac complications in this 
case is probably caused by the high intensity of treatment 
as well as the synergistic cardiotoxic effect of radiotherapy 
and the anthracyclines in the CWS 2006 protocol [14].
The occurrence of PD, after 15 months of intensive 
combined therapy, confirms that patients with dissem-
inated RMS are characterised by a very unfavourable 
prognosis after using standard methods of treatment. 
Despite the efforts of many research groups, the results of 
the treatment have not yet been significantly improved. 
Therefore, it seems necessary to constantly develop local 
and systemic methods of treatment. 
In the above case, only partial resection of the prima-
ry tumour was possible. A novel method of the treatment, 
described in the literature, ensuring complete resection, is 
heart transplantation [15, 16]. New radiotherapeutic tech-
niques, such as intensity-modulated radiation therapy 
(IMRT), proton therapy, and brachytherapy, are continu-
ing to improve treatment results by increasing the radia-
tion dose delivered to the tumour site with less radiation 
of surrounding tissues [17]. It will certainly improve the 
results of treatment of non-diffuse disease.
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In recent years, despite numerous studies investigat-
ing the modification of chemotherapy, using maintenance 
chemotherapy and myeloablative therapy, no significant 
improvement in the treatment outcomes was observed in 
either paediatric or adult patients. Therefore, particularly 
high expectations in the future are associated with the 
introduction of targeted therapies, using numerous ab-
normalities in intracellular pathways found in RMS [18]. 
The most important and recent reports concerning the 
use of this class of drugs in RMS are presented in Table 1. 
Perhaps their use will lead to improved prognosis in this 
group of patients.
CONCLUSIONS
The presented case description raises a difficult clinical 
problem. In a patient with disseminated RMS embryonale 
anaplastic variant, with an ultra-rare primary tumour loca-
tion, despite the use of combined treatment, only a short-
term partial remission of the disease was obtained. Due to 
the progression of the disease and resistance to successive 
lines of chemotherapy, the patient died. Undoubtedly, new 
and innovative methods of treatment are needed to im-
prove survival in this specific group of patients.
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